Circassia Pharmaceuticals (CIR) Given Buy Rating at Peel Hunt

Share on StockTwits

Peel Hunt restated their buy rating on shares of Circassia Pharmaceuticals (LON:CIR) in a research report sent to investors on Wednesday, October 3rd.

Separately, Numis Securities restated a buy rating and issued a GBX 140 ($1.83) price objective on shares of Circassia Pharmaceuticals in a report on Thursday, September 27th.

Shares of CIR opened at GBX 75.90 ($0.99) on Wednesday.

Circassia Pharmaceuticals Company Profile

Circassia Pharmaceuticals plc, a specialty biopharmaceutical company, focuses on the development and commercialization of products for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It markets novel NIOX asthma management products directly to specialists in the United States, the United Kingdom, and Germany, as well as through a network of partners internationally.

Further Reading: How to Invest in Growth Stocks

Receive News & Ratings for Circassia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.